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Introduction
The central role of tumour necrosis factor (TNF-α) in the
initiation and/or perpetuation of the inflammatory
processes in rheumatoid arthritis (RA), Crohn’s disease
(CD) and many more chronic inflammatory diseases has
been suggested by experimental in vitro and in situ data.
This has been clearly verified by the overwhelming
success of TNF-α-targeted therapies. Thus, a lot of enthu-
siasm has been put into the development of further strate-
gies aimed at blocking TNF-α with new and innovative
drugs (immunobiologicals and synthetic inhibitors of
TNF-α synthesis or signal transduction). Furthermore, new
indications for TNF-α-targeted treatment are forthcoming.
Rheumatoid arthritis and Crohn’s disease:
future directions
Further studies with immunobiologicals
After TNF-α-targeting immunobiologicals like etanercept
and infliximab have been approved for the treatment of
Crohn’s disease, rheumatoid arthritis and juvenile chronic
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Chapter summary
Rheumatoid arthritis (RA) is the most common chronic autoimmunopathy, clinically leading to joint
destruction as a consequence of the chronic inflammatory processes. The pathogenesis of this
disabling disease is not well understood, but molecular events leading to tissue inflammation with
cartilage and bone destruction are now better defined. Therapy with slow-acting, disease-modifying
antirheumatic drugs (DMARDs), such as low-dose methotrexate, which is generally accepted as a
standard, leads to a significant amelioration of symptoms but does not stop joint destruction. Due to
these disappointing treatment options and the identification of certain inflammatory mediators as
therapeutic targets, novel therapeutic agents such as monoclonal antibodies, cytokine-receptor/
human-immunoglobulin constructs or recombinant human proteins have been tested in RA with some
success. Clinical trials testing anti-TNF-α agents, alone or in combination with methotrexate, have
convincingly shown the feasibility and efficacy of these novel approaches to the therapy of RA. A
clinical trial testing combination therapy with chimeric (mouse/human) anti-TNF-α monoclonal
antibody infliximab and methotrexate showed, for the first time in any RA trial, that there was no
median radiological progression in the groups given infliximab plus methotrexate over a 12-month
observation period. Similar encouraging results might arise from trials employing other TNF-α-
directed agents, such as the fully human monoclonal antibody D2E7, the p75 TNF-α-receptor/Ig
construct, etanercept, or others, as discussed in this review. Combination partners other than
methotrexate will be established as suitable cotreatment along with anti-TNF-α biologicals.
Forthcoming new indications for TNF-α-targeted therapies are discussed.
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arthritis, further steps will be taken to establish this thera-
peutic principle for treatment of other chronic inflamma-
tory diseases. These developments may include
additional clinical trials with the established agents, or
clinical studies with new TNF-α-targeting immunobiologi-
cals, such as the human D2E7 antibody [1]. Other TNF-α
blocking agents are also being developed (e.g. poly-
ethylenglycol [PEG]-bound p55 TNF-receptor [PEG-
TNFRI] [2] or the PEGylated TNF-α antibody fragments
[CDP-870]). A soluble type 1 p55 TNF-receptor
(onercept) is currently being tested in CD. Further long-
term observations are required concerning side effects
and efficacy of these agents, focusing particularly on radi-
ological progression under therapy with anti-TNF agents
in combination with methotrexate. This information is
required specifically for the combinations of etanercept
plus methotrexate and D2E7 plus methotrexate in
patients with RA, but needs to be determined for all new
agents.
To date, TNF-α blockade is only recommended for
therapy-resistant cases. A clinical trial has been initiated
testing efficacy in RA patients in an early phase of their
disease. This will be especially interesting since one
could hypothesize that early and effective blockade of
the chronic inflammatory processes in RA will be more
efficient. This should lead to the prevention of tissue
destruction and disability as well as higher frequencies
of long-term remissions, compared to situations where
treatment is semi-efficient with perpetuating inflammation
over years. These studies might, therefore, help to define
criteria that prospectively characterize an RA patient as
one with better prognosis (and defensive therapeutic
strategy) versus a worse prognosis with a requirement
for aggressive treatment from the beginning of his/her
disease. Prospective parameters could include HLA
type, radiological signs of joint desruction early after
disease onset or a high number of involved joints at the
beginning of the disease. It is unclear to date whether
the presence of TNF-α-promoter polymorphisms can
predict the severity of RA, but certain promoter polymor-
phisms could be another discriminator that might dictate
early, aggressive therapy.
Alternative combination partners
Since methotrexate is generally accepted as the standard
first line disease-modifying antirheumatic drug (DMARD)
in RA, most of the anti-TNF-α trials have been performed
with this combination partner. However, not all patients
respond to, or tolerate, methotrexate, so alternative combi-
nation partners substituting methotrexate are warranted.
Leflunomide is currently being tested along with infliximab
in RA patients. Azathioprin, cyclosporin A or sulfasalazine
might be alternative candidates [3]. This will considerably
increase the spectrum of therapeutic modalities affiliated
with the TNF-α-targeting drugs.
New indications for TNF-α α-targeting therapies
Psoriatic arthritis and psoriasis
The prevalence of psoriasis is reported as 1–3% of adults
in the United States, and psoriatic arthritis (PsA) occurs in
approximately 6–20% of psoriasis patients [4]. Psoriatic
arthritis is an inflammatory arthropathy that may develop
before skin involvement. It presents in a symmetric or asym-
metric polyarticular form, with or without onycholysis. The
current therapeutic approaches for PsA are similar to those
for RA and include nonsteroidal anti-inflammatory drugs
(NSAIDs), DMARDs and immunosuppressive agents. Only
two DMARDs, methotrexate and sulfasalazine, have
demonstrated efficacy in the treatment of PsA.
Circulating T lymphocytes and macrophages isolated from
PsA patients produce an increased amount of TNF-α com-
pared with macrophages isolated from healthy controls [5].
Furthermore, the levels of TNF-α are elevated in the synovial
fluid [6], tissue [6,7] and skin lesions [8,9] in PsA patients,
with TNF-α levels correlating with disease activity [10,11].
As a logical consequence, studies with TNF-α-blocking
biologicals were initiated. Several open-label studies have
investigated the use of anti-TNF-α agents in the treatment
of PsA and psoriasis [12–16]. In a single-centre, open-
label report on the treatment of spondyloarthropathies, van
den Bosch et al. [12] reported that nine PsA patients
treated with infliximab (5 mg/kg at weeks 0, 2 and 6) expe-
rienced significant improvement in physician’s global
assessment (PGA), erythrocyte sedimentation rates
(ESR), and C-reactive protein (CRP) levels. Of these
patients, eight had psoriasis at baseline. After 12 weeks of
infliximab treatment, baseline Psoriasis Area and Severity
Index (PASI) scores were significantly improved. The clini-
cal improvements in all PsA and psoriasis disease mani-
festations were maintained over a follow-up period of
1 year [13]. In another open-label study, eight out of 10
heavily pretreated PsA patients experienced improve-
ments in Health Assessment Questionnaire scores and
PGA scores after 12 months of treatment with etanercept
(25 mg given subcutaneously twice a week). All four
patients in this trial with active psoriasis had significant
improvement in their psoriatic skin lesions, including com-
plete resolution in three patients [14].
In our open-label experience, infliximab treatment was effi-
cacious and safe in PsA and psoriasis [15,16]. With inflix-
imab treatment (5 mg/kg at weeks 0, 2, and 6), all 10
patients in our study achieved 20% improvement in arthritis
according to the American College of Rheumatology
response criteria (ACR20) by week 2. After 10 weeks of
treatment, eight patients achieved 70% improvement
(ACR70), six of whom maintained this improvement to
week 54. In addition, magnetic resonance imaging showed
an 82% reduction in perfusion of inflamed joints, and mean
PASI scores were reduced by 71% at week 10. After 10S19
weeks of infliximab therapy, six patients experienced nearly
complete clearing of erythematous psoriasis plaques.
Histopathological analysis of psoriatic plaques showed a
reduction in epidermal hyperplasia and inflammation by
week 10 [16]. This reduction in hyperplasia was associ-
ated with a decrease in plaque size and was evident by the
near-normal epidermal structure after infliximab treatment.
In a more detailed analysis we recently showed that,
besides a decrease of the cellular infiltration (lymphocytes,
granulocytes), the protein expression of TNF-α, intercellular
adhesion molecule-1 and leukocyte function-associated
antigen-1, the mRNA expression of IL-8, IL-20 and TNFR
type I were significantly lower in psoriatic plaques after
4 weeks of treatment (Ogilvie et al., submitted). The use of
anti-TNF-α agents in treating PsA and psoriasis has also
been investigated in a randomized, double-blinded,
placebo-controlled study. Mease et al. [17] reported that
87% patients receiving etanercept (25 mg subcutaneously
twice a week) achieved PsA response criteria, compared
with 23% of placebo patients (P < 0.0001). In addition,
73% of etanercept-treated patients achieved ACR20 com-
pared with 13% of placebo-treated patients (P<0.0001).
Of 19 patients in each treatment group with active psoria-
sis, the median improvement in PASI scores was signifi-
cantly higher in etanercept-treated patients than in
placebo-treated patients. Of psoriasis patients treated with
etanercept, 26% achieved a 75% improvement, whereas
no patients improved when treated with placebo. In an
open-label extension study, etanercept continued to effec-
tively reduce clinical signs and symptoms of PsA and psori-
asis for up to 36 weeks [18].
Recently, Chaudhari et al. [19] described the first reported
placebo-controlled, randomized study designed to investi-
gate the efficacy of an anti-TNF agent in psoriasis patients.
In this study, 30 patients ware randomized to receive inflix-
imab (5 or 10 mg/kg) or placebo. Nine of 11 (82%)
patients treated with infliximab at 5 mg/kg achieved good,
excellent, or clear ratings on PGA, compared with only
2/11 (18%) patients receiving placebo (P = 0.0089). In
addition, 10/11 (91%) patients treated with infliximab at
10 mg/kg achieved these ratings (P = 0.0019 compared
to placebo). A significantly higher proportion of patients
treated with infliximab obtained a 75% improvement in
PASI scores compared with placebo (P = 0.0089, inflix-
imab 5 mg/kg versus placebo; P = 0.03, infliximab
10 mg/kg versus placebo). The results of these studies
suggest that TNF-α plays a pivotal role in the pathogene-
sis of PsA and psoriasis. In addition, anti-TNF-α therapy
offers patients with PsA and psoriasis a new therapeutic
option for the control of their disease.
Ankylosing spondylitis
Ankylosing spondylitis (AS) is an inflammatory arthropathy
that preferentially affects the axial skeleton, usually mani-
festing in the sacroiliac joints and then ascending to
involve the back bone, frequently accompanied by periph-
eral arthritis. Treatment for AS includes NSAIDs and sul-
fasalazine, which is the only DMARD that shows activity in
the disease, albeit only for peripheral joints.
Only limited evidence exists to support a role for TNF-α in
the pathophysiology of AS. Braun et al. [20] showed that
TNF-α mRNA and protein were present in inflamed
sacroiliac joints of AS patients. Lange et al. [21] reported
significantly increased TNF-α plasma levels in AS patients,
with a positive correlation between TNF-α plasma levels
and the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI). In addition, the strong link between AS and
inflammatory bowel disease, where 20–60% of spondy-
loarthropathy patients have gastrointestinal lesions resem-
bling those in CD, provides circumstantial evidence for a
role of TNF-α in AS [22].
In an open-label study, 11 patients with AS of short dura-
tion were treated with infliximab (5 mg/kg at weeks 0, 2,
and 6) [23]. Improvements in activity, function and pain
scores of ≥50% were reported in 9/10 eligible patients.
The median CRP level decreased to normal and the
median improvement in BASDAI score after 4 weeks was
70%. In another open-label study of patients with different
subtypes of spondyloarthropathy, 10 AS patients treated
with infliximab at 5 mg/kg every 14 weeks achieved signifi-
cant improvements in morning stiffness, tender and
swollen joint counts, ESR, CRP, BASDAI score, Bath
Ankylosing Spondylitis Functional Index score, and Bath
Ankylosing Spondylitis Metrology Index score. Improve-
ment in the other endpoints were significant at days 3–14
and were maintained to day 84 or longer [13].
In a larger open-label study, 48 patients with severe AS
were treated with infliximab. At week 8, significant improve-
ments in mean disease activity, global pain, BASDAI score,
Bath Ankylosing Spondylitis Functional Index score, and
CRP levels were observed [24]. The results of the afore-
mentioned open-label studies were recently confirmed in a
double-blind, placebo-controlled, phase III clinical trial [25].
A total of 70 patients with active AS were enrolled in the
study and randomized to receive placebo (n = 35) or inflix-
imab at 5 mg/kg (n = 35) at weeks 0, 2 and 6, and then
every 6 weeks until week 48. At the time of the report, 66
patients had completed 3 months of treatment. A 50%
improvement in BASDAI score was achieved by 53% of
patients treated with infliximab, compared with 9% of
patients treated with placebo (P < 0.01). Interestingly, only
patients with elevated serological markers of inflammation
responded to anti-TNF-α therapy. Similar data have
recently been reported with etanercept in AS patients [26].
Adult-onset Still’s disease
Adult-onset Still’s disease (AOSD) is a rare systemic
inflammatory disorder of unknown etiology. Clinical
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symptoms of this disease are high spiking fever, arthritis,
transient cutaneous rashes, hepatosplenomegaly, leukocy-
tosis and sore throat. A markedly elevated serum ferritin
correlates with disease activity and several inflammatory
cytokines are elevated in these patients. Furthermore,
Hoshino  et al. [27] reported elevated serum levels of
TNF-α in AOSD patients. Recently, Kawashima et al. [28]
demonstrated that the proinflammatory cytokine IL-18 is
markedly, and in this quantity rather specifically, elevated
in the serum of AOSD patients during the acute phase of
their disease. Because it has been shown that TNF-α
induces the expression of IL-18 in synovial tissues [29],
anti-TNF agents may lead to a reduction of IL-18 in AOSD
patients. Bombardieri et al. [30] recently demonstrated
that infliximab reduced IL-18 serum levels in RA patients.
Therefore, studies to determine if infliximab also reduces
IL-18 serum levels in AOSD are warranted.
The current treatment for AOSD is mostly limited to the
use of NSAIDs and, in severe cases, prednisone.
However, many patients become dependent on high-dose
prednisone or are refractory to corticosteroid treatment. In
a retrospective analysis of 26 AOSD patients, methotrex-
ate was an effective second-line treatment for patients
who had not responded to prednisone. However, con-
trolled studies of methotrexate and other DMARDs in the
treatment of AOSD have not been performed. Thalido-
mide, a known inhibitor of TNF-α, was reported to
markedly improve clinical symptoms in a patient with treat-
ment-resistant AOSD [31].
Systematic investigation of anti-TNF-α therapy in AOSD is
in its early stages. An open-label trial evaluated the effi-
cacy of infliximab in the treatment of AOSD refractory to
conventional therapy [32]. Three patients with chronic and
active AOSD who were unresponsive to corticosteroids
and methotrexate were administered infliximab at 3 mg/kg
at weeks 0, 2, and 6, and then every 8 weeks thereafter,
along with concomitant methotrexate (15 mg/week). At
50 weeks of follow up, disease activity improved in all
three patients, and two patients experienced reductions in
ESR, CRP, prednisone dose and PGA. In a recent pilot
study conducted at our institution, six AOSD patients
treated with infliximab reported marked improvements in
the clinical signs and symptoms of AOSD [33]. Patients
were treated with infliximab at 5 mg/kg at weeks 0, 2, and
6, and thereafter at intervals of 6–8 weeks. In all six
patients, fever, arthralgias, myalgias, splenomegaly and
rash were resolved within the first three courses of inflix-
imab treatment. Although the results of these open-label
trials need to be confirmed in randomized, placebo-con-
trolled studies, preliminary results suggest that infliximab is
effective in managing relapses in refractory AOSD
patients. This has meanwhile been confirmed by another
group [34]. Tamesis et al. [35] treated five AOSD patients
with etanercept (2 × 25 mg/week, subcutaneously) with
good success in all disease parameters up to 12 months.
Weinblatt  et al. [36] treated 12 patients with etanercept
(initial dosage 2 × 25 mg/week, subcutaneously). Of these
12 patients, two withdrew because of disease flares and
four had to increase their etanercept dosage to
3 × 25 mg/week. In the three patients with fever and rash,
only one improved in these features.
Polymyositis and dermatomyositis
Polymyositis and dermatomyositis are idiopathic inflamma-
tory myopathies that are characterized by proximal muscle
weakness, skeletal muscle inflammation and damage, and
elevated serum levels of muscle-derived proteins such as
creatinine kinase. Polymyositis is associated with lympho-
cyte invasion of muscle fibres, predominantly cytotoxic
CD8+ T lymphocytes, which leads to muscle fibre necro-
sis, degeneration and fibrosis. The current first-line therapy
for polymyositis is prednisone. However, many patients
only achieve partial response or do not respond at all to
high dose corticosteroids. Because early recognition and
treatment of polymyositis is critical to prevent irreversible
muscle damage, second-line therapies such as methotrex-
ate or azathioprine should be administered to patients who
fail to respond to corticosteroid treatment. Alternatively, or
in addition, high dose immunoglobulins have been proven
efficacious in refractory cases.
Using monoclonal antibodies to TNF-α, Tateyama et al. [37]
demonstrated that TNF-α positive macrophages and lym-
phocytes invade the endomysium in the muscles of
polymyositis patients. In addition, the authors describe a cor-
relation between TNF-α levels in the endomysium and
muscle fibre atrophy. Kuru et al. [38] also demonstrated infil-
tration of TNF-α-positive CD8+ lymphocytes and
macrophages into the muscle fibres of polymyositis patients.
The apparent involvement of cytokine-producing T lympho-
cytes in polymyositis has initiated interest in treating these
patients with anti-TNF agents. Saadeh [39] treated four
refractory patients with dermatomyositis with satisfying
benefit. Hengstman et al. [40] treated two dermatomyosi-
tis patients with infliximab (10 mg/kg every second week)
with good responses. We recently treated a patient with
polymyositis refractory to immunosuppressive regimens
with infliximab (4 mg/kg every 6 weeks) and concomitant
methotrexate therapy. This patient showed a significant
response to infliximab treatment, including a significant
improvement in mobility. The skeletal muscle-specific
enzymes returned to normal serum levels, indicating a sub-
stantial reduction in inflammation. However, this could not
be confirmed in another patient. Although this is a single
case, it suggests that anti-TNF-α therapy may be a viable
treatment alternative for certain patients with refractory
polymyositis. Further studies to fully investigate the poten-
tial for anti-TNF-α therapy in treating polymyositis are
warranted .
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Vasculitis (Behçet’s disease, Wegener’s granulomatosis)
Behçet’s disease is a chronic autoimmune disorder char-
acterized by systemic vasculitis. This disease is associ-
ated with mucocutaneous, ocular, articular, vascular,
gastrointestinal and central nervous system manifesta-
tions. Approximately 70% of patients experience relapsing
ocular inflammation that can lead to blindness. The etiol-
ogy of Behçet’s disease is unknown, although a genetic
association to human leukocyte-associated antigen-B5
has been described [41]. However, some evidence sug-
gests that increased levels of TNF-α and soluble TNF
receptors are associated with active disease [42,43].
Thalidomide has been successfully used in the treatment
of Behçet’s disease, possibly by accelerating the degrada-
tion of TNF-α mRNA [44].
Recently, anti-TNF therapy has been used for the treat-
ment of these patients. Travis et al. [45] reported the suc-
cessful use of infliximab in two Behçet’s disease patients
with rare gastrointestinal ulcerations; this has been con-
firmed by others [46]. Within 10 days of infliximab treat-
ment, the ulcers had healed and all extraintestinal
manifestations had resolved. Furthermore, five patients
with relapsing panuveitis were successfully treated with
infliximab. Remission of ocular inflammation was evident
within the first 24 hours and complete suppression was
observed within 7 days of infliximab therapy [47]. This has
been confirmed in case reports by other authors [48,49];
treatment with infliximab (10 mg/kg, twice at week 0 and
4) has resulted in long-term remission over more than
12 months [49]. Clearly, the rapid and effective response
of this handful of Behçet’s disease patients to infliximab
warrants further studies of the use of anti-TNF therapy in
treating this disease.
Wegener’s granulomatosis (WG) is a chronic necrotizing
vasculitis involving small to middle-sized vessels. Virtually
every organ can be involved, but typically eyes, lungs,
joints and kidneys are affected. It is characterized by the
occurrence of cytoplasmic antineutrophil cytoplasmic
antigen antibodies directed against proteinase 3. The pro-
duction of TNF-α in peripheral blood mononuclear cells
and CD4+ T cells isolated from patients with WG was
elevated, when compared with healthy donors [50]. More-
over, Noronha et al. [51] found expression of TNF-α at
active sites of inflammation in kidney biopsies.
Consequently, a clinical study with infliximab in patients
with WG was initiated [52]. Six patients who were refrac-
tory to therapy with cyclophosphamide were treated with
infliximab at 3–5 mg/kg (day 0, weeks 2 and 6, every fourth
week thereafter). Three patients had imminent visual loss
due to progressive retroorbital granulomas, two patients
had progressive glomerulonephritis, and one patient suf-
fered from progressive pulmonary granulomas. Infusion of
infliximab resulted in a rapid and significant improvement in
five patients, one patient was withdrawn due to suspected
infection. Similar results were reported by Bartolucci et al.
in 10 patients (seven with WG, two with RA-associated
systemic vasculitis and one with cryoglobulinemic vasculi-
tis) [53]. In a randomized trial with active WG, 20 patients
were enrolled for treatment with etanercept
(2 × 25 mg/week, subcutaneously) on methotrexate back-
ground. All patients could taper their steroid dosage within
6 months. Long-term efficacy data are not available so far
[54]. In another study, Stone et al. [55] included 20 active
WG patients. Etanercept was added to the standard thera-
peutic regime including cyclophosphamide in six patients.
Nineteen out of the 20 patients remained on the drug over
the observation period of 6 months, one patient developed
retroorbital granulomas at 4 months. Birmingham Vasculitis
Activity Score decreased from 3.6 to 0.6, and the mean
daily prednisolone dosage could be reduced from 19 mg
to 7.4 mg. However, persistently active disease was
common and present in 15/19 patients; one patient devel-
oped renal involvement and mesenteric vasculitis while
taking etanercept.
New nonbiological TNF-α α-targeting agents
Given the high costs associated with immunobiologicals
and the need for saving expenses in virtually every health
care system worldwide, a specific TNF-α blockade
employing synthetic (and therefore less expensive) agents
is most desirable. Another advantage would be the possi-
ble oral availability of these drugs. In this context, inhibition
of TNF-α gene transcription, inhibition of TNF-α mRNA
translation or blockade of TNF-α-specific signal transduc-
tion could be envisioned. A 10 amino acid peptide could
block TNF-α synthesis at the translational level both in
vitro and in vivo (rat arthritis model; murine colitis model)
through unknown mechanisms. A TNF-α mRNA antisense
construct (ISIS 25302) might qualify as a further drug with
high specificity. However, both drugs must be evaluated
for efficacy and safety in preclinical and clinical trials in
both animals and humans.
Insights into signal transduction events associated with
TNF-α and/or other proinflammatory cytokines enable tar-
geting of intracellular key molecules, thereby blocking con-
sequences of TNF-α signaling at the subreceptor level.
One needs to keep in mind, however, that, so far, there are
no chemical signal transduction inhibitors that are 100%
specific for one certain kinase; so the side effects might be
less favorable than the immunobiologicals. Moreover, many
(probably most) intracellular signaling enzymes are not
completely specific for one certain signalling cascade, but
are redundantly employed by various receptor-associated
signalling cascades. This is not necessarily a disadvantage,
but bears the risk for a broader spectrum of side effects.
One of the therapeutic target structures involved in the
TNF-α associated signalling cascades is p38 mitogen-
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activated protein kinase (MAPK), which is important for
the initiation of TNF-α synthesis [56]. Thus, ‘specific’
inhibitors of p38 MAPK were developed (SCIO-469;
VX-745; BIRB 796), which are currently being evaluated
in animal models. At high dosage, BIRB 796 has been
shown to effectively inhibit arthritis progression in estab-
lished collagen-induced arthritis [57].
Thalidomide has TNF-α inhibiting properties which might
be centrally mediated through inhibition of phosphodi-
esterase IV. Disadvantages of this old drug are obviously
affiliated to its teratogenicity and sedative properties.
Several companies are in the course of developing phos-
phodiesterase-IV-dependent or -independent thalidomide
derivatives with similar TNF-α neutralising efficacy, but
lower toxicity. Roflumilast, an orally available selective
phosphodiesterase IV inhibitor, has been shown to
decrease TNF-α concentrations in a lipopolysaccharide
model, both in vivo and in vitro, and to protect mice in the
collagen-induced arthritis model, especially in combination
with methotrexate [58].
Nuclear factor (NF)-κB is responsible for both synthesis of
TNF-α as well as transmission of TNF-α-mediated effects
[56,59]. NF-κB is a p50/p65 heterodimer which is bound
to, and inactivated by, its inhibitor, IκB. After activation of
the cell, IκB-kinases (IκK) phosphorylate and degrade IκB,
enabling NF-κB to translocate into the nucleus and to bind
to its specific promoter sites. An inhibition of IκK will
thereby indirectly block transmission of TNF-α-associated
intracellular signals [60]. Several IκK inhibitors have been
developed, but to our knowledge none is yet in preclinical
trials in humans. In DBA/1 mice, collagen-induced arthritis
was treated with two IκK inhibitors, AS 2868 or AS 2920,
at occurrence of first signs of the disease [61]. Disease
severity was dose-dependently decreased, particularly by
AS 2920. In an adjuvant arthritis model in Lewis rats, the
IκK inhibitor, SPC-839, was orally given in various doses
once daily. The authors describe a dose-dependent
decrease in paw swelling and a near complete inhibition of
radiographic damage, associated with improvement of his-
tological features [62].
Another strategy focuses on TNF-α converting enzyme
(TACE), a metalloproteinase that is important for cleavage
of membrane-bound TNF-α. Inhibitors of TACE could
prevent secretion of TNF-α and possibly decrease con-
centrations of (soluble) TNF-α at the inflammatory site. On
the other hand, Kollias and his group have shown that
overexpression of only the membrane-bound TNF-α in
mice still leads to a chronic destructive arthritis [63]. In
addition, TACE is responsible for the cleavage of TNF-α
receptors, thereby preventing solubilization of these
natural TNF-α binding and neutralizing proteins. Therefore,
TACE inhibitors might not only have anti-inflammatory
properties.
An orally available TACE inhibitor, DPC 333, has been
successfully tested in several mouse and rat models of
arthritis. A double-blind, placebo-controlled, phase IIa
study in RA patients was initiated, but has been put on
hold after the merging of Bristol-Myers Squibb and
DuPont Pharmaceuticals.
Concluding remarks
The overwhelming success of TNF-α-targeting therapies
in treatment of RA, CD and juvenile chronic arthritis has
lead to an avalanche of new therapeutic trials aiming at
neutralising TNF-α, including long-term treatment in RA
patients, introduction of new anti-TNF-α immunobiologi-
cals, new indications for TNF-α blockade and (yet still
quite early in development) orally available inhibitors of
TNF-α synthesis or signal transduction. Both patients and
physicians can optimistically await the next years, as new
agents and study results will considerably broaden the
range of improved therapeutic options in chronic inflam-
matory diseases.
Glossary of terms
ACR 20 (50) (70) = American College of Rheumatology
criteria for 20% (50%)(70%) improvement; AOSD = Adult
onset Still’s disease; AS = ankylosing spondylitis;
BASDAI = Bath Ankylosing Spondylitis Disease Activity
Index; CD = Crohn’s disease; PASI = psoriasis area and
severity index; PDE = phosphodiesterase; PGA = physi-
cian’s global assessment; PsA = psoriatic arthritis;
TACE = TNF-α converting enzyme; WG = Wegener’s
granulomatosis.
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